Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth

{
  "signal_id": "0bf7e415-fb2d-146b-3394-abe3f265a2e2",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-17T14:31:00+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/paroxysmal-nocturnal-hemoglobinuria-market-forecast-upto-2036-5-emerging-therapies-poised-to-accelerate-market-growth--delveinsight-302881393.html",
    "title": "Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight",
    "excerpt": "The expected launch of potential therapies such as Pozelimab + Cemdisiran (Regeneron Pharmaceuticals), Zaltenibart (OMS906; Novo Nordisk), Ruxoprubart (NM8074; NovelMed Therapeutics), NM5072 (NovelMed Therapeutics), ADX-038 (ADARx Pharmaceuticals), KP104 (Kira Pharmaceuticals), and others may increase the paroxysmal nocturnal hemoglobinuria market size in the coming years, assisted by an increase in the diagnosed prevalent population of PNH. LAS VEGAS , Sept. 17, 2026 /PRNewswire/ -- Until 2007, paroxysmal nocturnal hemoglobinuria (PNH) was a life-threatening disorder with limited therapeutic options for controlling hemolysis and thrombosis, the latter being a major contributor to mortality. The treatment landscape underwent a significant transformation with the introduction of the anti-C5 complement inhibitor eculizumab, which substantially reduced hemolysis, lowered transfusion requirements, and, importantly, decreased the risk of thrombosis. The current disease-modifying treatment approach for PNH is centered on complement inhibition. FDA-approved therapies, including SOLIRIS (eculizumab), ULTOMIRIS (ravulizumab), and EMPAVELI (pegcetacoplan) , have established complement inhibition as the standard of care. However, limitations and safety considerations associated with terminal complement inhibition have driven the development of alternative therapeutic approaches. More...",
    "product": "Pozelimab + Cemdisiran",
    "summary": "Regeneron Pharmaceuticals is developing Pozelimab + Cemdisiran, a potential therapy for paroxysmal nocturnal hemoglobinuria (PNH).",
    "planning": true,
    "image_url": "https://mmx.prnewswire.com/media/MS1196378/logo-png.jpg?id=OA2954770&p=facebook",
    "confidence": 0.9,
    "product_data": {
      "name": "Pozelimab + Cemdisiran",
      "full_text": "Pozelimab + Cemdisiran",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-09-17T14:31:00Z",
    "article_sentence": "The expected launch of potential therapies such as Pozelimab + Cemdisiran (Regeneron Pharmaceuticals), Zaltenibart (OMS906; Novo Nordisk), Ruxoprubart (NM8074; NovelMed Therapeutics), NM5072 (NovelMed Therapeutics), ADX-038 (ADARx Pharmaceuticals), KP104 (Kira Pharmaceuticals), and others may increase the paroxysmal nocturnal hemoglobinuria market size in the coming years, assisted by an increase in the diagnosed prevalent population of PNH."
  }
}

curl https://signals.autobound.ai/v1/signals/0bf7e415-fb2d-146b-3394-abe3f265a2e2 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"regeneron.com","limit":20}'